Characteristics and Treatment Patterns of People Without Type 2 Diabetes Diagnoses Who Use Tirzepatide in the United States.

Gibble TH, Hankosky ER, Meeks A, Liao B, Ward J, Huang A, Chinthammit C

Clinical therapeutics6 Jun 2025

PMID40480878DOI10.1016/j.clinthera.2025.05.003PepBankPUB-40480878

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyOther
In US adults without type 2 diabetes diagnoses, tirzepatide persistence ranged from 60.6% to 75.7% across both databases, depending on the allowed gap between prescriptions.
In plain wordsIn US adults without type 2 diabetes, 60.6% to 75.7% stayed on tirzepatide, depending on how a gap between prescriptions was counted.
Peptide
Tirzepatide
Outcome
Not applicableTirzepatide persistence at 6 months
Study
n: not reported in source
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated
Measurements
Persistence
60.6 to 75.7%
both databases, 45 or 60 day gap
Source sentences
Summary
Tirzepatide persistence ranged from 60.6% to 75.7% across both databases, with an allowed gap between prescriptions of 45 days or 60 days.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, observational, descriptive study used data from the MarketScan and Optum CDM databases (index date: first-observed Tirzepatide claim) from May 2021 to September 2023.
Summary · context
Key eligibility criteria included age ≥18 years, ≥1 Tirzepatide claim, no baseline T2D diagnosis codes or antihyperglycemic medication use (except metformin), and continuous medical and pharmacy enrollment for ≥12 months pre-index.
Report a problemFND-4048087801
02HumanObservational studyOther
In US adults without type 2 diabetes diagnoses who discontinued tirzepatide, 10.2-19.5% restarted it during the 6-month follow-up.
In plain wordsIn US adults without type 2 diabetes who stopped tirzepatide, 10.2% to 19.5% restarted within 6 months.
Peptide
Tirzepatide
Outcome
Not applicableRestart of tirzepatide after discontinuation
Study
n: not reported in source
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated
Measurements
Restarted tirzepatide
10.2 to 19.5%
among those who discontinued
Source sentences
Summary
Of individuals who discontinued tirzepatide, 10.2-19.5% restarted Tirzepatide during the 6-month follow-up.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, observational, descriptive study used data from the MarketScan and Optum CDM databases (index date: first-observed Tirzepatide claim) from May 2021 to September 2023.
Summary · context
Key eligibility criteria included age ≥18 years, ≥1 Tirzepatide claim, no baseline T2D diagnosis codes or antihyperglycemic medication use (except metformin), and continuous medical and pharmacy enrollment for ≥12 months pre-index.
Report a problemFND-4048087802
03HumanObservational studyOther
In US adults without type 2 diabetes diagnoses, about two-thirds of people started tirzepatide at 2.5 mg in both databases.
In plain wordsIn US adults without type 2 diabetes, about two in three people started tirzepatide at 2.5 mg.
Peptide
Tirzepatide
Outcome
Not applicableStarting dose of tirzepatide
Study
n: not reported in source
Outcome group
Patterns of use · Whole body
Studied dose
2.5 mgAs given in this study (human).
Source sentences
Summary
In both databases, approximately two-thirds of people were started on 2.5 mg
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, observational, descriptive study used data from the MarketScan and Optum CDM databases (index date: first-observed Tirzepatide claim) from May 2021 to September 2023.
Summary · context
Key eligibility criteria included age ≥18 years, ≥1 Tirzepatide claim, no baseline T2D diagnosis codes or antihyperglycemic medication use (except metformin), and continuous medical and pharmacy enrollment for ≥12 months pre-index.
Report a problemFND-4048087803
04HumanObservational studyOther
In US adults without type 2 diabetes diagnoses, the most common tirzepatide doses by the sixth prescription fill were 5 mg and 7.5 mg.
In plain wordsIn US adults without type 2 diabetes, 5 mg and 7.5 mg were the most common tirzepatide doses by the sixth fill.
Peptide
Tirzepatide
Outcome
Not applicableMost common doses by sixth prescription fill
Study
n: not reported in source
Outcome group
Patterns of use · Whole body
Studied dose
5 mg and 7.5 mgAs given in this study (human).
Source sentences
Summary
by the sixth prescription fill, the most common doses of Tirzepatide were 5 mg and 7.5 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, observational, descriptive study used data from the MarketScan and Optum CDM databases (index date: first-observed Tirzepatide claim) from May 2021 to September 2023.
Summary · context
Key eligibility criteria included age ≥18 years, ≥1 Tirzepatide claim, no baseline T2D diagnosis codes or antihyperglycemic medication use (except metformin), and continuous medical and pharmacy enrollment for ≥12 months pre-index.
Report a problemFND-4048087804
05HumanObservational studyOther
In US adults without type 2 diabetes diagnoses who used tirzepatide, 70.6% (MarketScan) and 81.0% (Optum CDM) had at least one obesity-related complication, most often hypertension, dyslipidemia and pre-diabetes.
In plain wordsIn US adults without type 2 diabetes who used tirzepatide, most had at least one obesity-related health problem, such as high blood pressure.
Peptide
Tirzepatide
Outcome
Not applicableObesity-related complications at baseline
Study
n: not reported in source
Outcome group
Patterns of use · Whole body
Studied dose
Dose not stated
Measurements
Individuals with at least one obesity-related complication
70.6%
MarketScan
Individuals with at least one obesity-related complication
81%
Optum CDM
Source sentences
Summary
A total of 70.6% (MarketScan) and 81.0% (Optum CDM) of individuals had at least one obesity-related complication, with the most prevalent being hypertension, dyslipidemia, and pre-diabetes.
Report a problemFND-4048087805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.